Author
Listed:
- Gail P. Risbridger
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre)
- Ashlee K. Clark
(Monash University)
- Laura H. Porter
(Monash University)
- Roxanne Toivanen
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne)
- Andrew Bakshi
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Natalie L. Lister
(Monash University)
- David Pook
(Monash University
Monash University
Monash Health)
- Carmel J. Pezaro
(Monash University
Eastern Health and Monash University Eastern Health Clinical School
Sheffield Teaching Hospitals NHS Foundation Trust)
- Shahneen Sandhu
(The University of Melbourne
Peter MacCallum Cancer Centre
Cancer Tissue Collection After Death (CASCADE) Program)
- Shivakumar Keerthikumar
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Rosalia Quezada Urban
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Melissa Papargiris
(Monash University
Monash University)
- Jenna Kraska
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
Monash University)
- Heather B. Madsen
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
Monash University)
- Hong Wang
(Monash University)
- Michelle G. Richards
(Monash University)
- Birunthi Niranjan
(Monash University)
- Samantha O’Dea
(Monash University)
- Linda Teng
(Monash University)
- William Wheelahan
(Monash University)
- Zhuoer Li
(Monash University)
- Nicholas Choo
(Monash University)
- John F. Ouyang
(Duke-National University of Singapore Medical School)
- Heather Thorne
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne)
- Lisa Devereux
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne)
- Rodney J. Hicks
(Peter MacCallum Cancer Center)
- Shomik Sengupta
(Eastern Health and Monash University Eastern Health Clinical School
The University of Melbourne
The University of Melbourne
Epworth Healthcare)
- Laurence Harewood
(Epworth Healthcare
The University of Melbourne)
- Mahesh Iddawala
(Monash University
Monash University)
- Arun A. Azad
(The University of Melbourne
Peter MacCallum Cancer Centre)
- Jeremy Goad
(The University of Melbourne
Epworth Healthcare
The University of Melbourne)
- Jeremy Grummet
(Epworth Healthcare
Monash University
Australian Urology Associates)
- John Kourambas
(Casey Hospital)
- Edmond M. Kwan
(Monash University
Monash Health)
- Daniel Moon
(Epworth Healthcare
The University of Melbourne
Australian Urology Associates
Monash University)
- Declan G. Murphy
(The University of Melbourne
Epworth Healthcare
The University of Melbourne)
- John Pedersen
(Monash University
TissuPath)
- David Clouston
(TissuPath)
- Sam Norden
(TissuPath)
- Andrew Ryan
(TissuPath)
- Luc Furic
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne)
- David L. Goode
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne
Peter MacCallum Cancer Centre)
- Mark Frydenberg
(Monash University
Epworth Healthcare
Australian Urology Associates
Monash University)
- Mitchell G. Lawrence
(Monash University
Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne)
- Renea A. Taylor
(Cancer Research Division, Peter MacCallum Cancer Centre
The University of Melbourne
Monash University)
Abstract
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012–2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer.
Suggested Citation
Gail P. Risbridger & Ashlee K. Clark & Laura H. Porter & Roxanne Toivanen & Andrew Bakshi & Natalie L. Lister & David Pook & Carmel J. Pezaro & Shahneen Sandhu & Shivakumar Keerthikumar & Rosalia Quez, 2021.
"The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology,"
Nature Communications, Nature, vol. 12(1), pages 1-17, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25175-5
DOI: 10.1038/s41467-021-25175-5
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- L. H. Porter & J. J. Zhu & N. L. Lister & S. G. Harrison & S. Keerthikumar & D. L. Goode & R. Quezada Urban & D. J. Byrne & A. Azad & I. Vela & M. S. Hofman & P. J. Neeson & P. K. Darcy & J. A. Trapan, 2023.
"Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models,"
Nature Communications, Nature, vol. 14(1), pages 1-17, December.
- Zifeng Wang & Scott L. Townley & Songqi Zhang & Mingyu Liu & Muqing Li & Maryam Labaf & Susan Patalano & Kavita Venkataramani & Kellee R. Siegfried & Jill A. Macoska & Dong Han & Shuai Gao & Gail P. R, 2024.
"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer,"
Nature Communications, Nature, vol. 15(1), pages 1-20, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25175-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.